Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas

NCT05415072 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05415072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05415072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 4, 2022
Completion date
October 1, 2027
Enrollment
66 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma